Munguva ichangopfuura, migumisiro yezvidzidzo zvitsva, inonzi Empagliflozin Cardiovascular Outcome Event Trial muTachipiri Cheshuga Mellitus Patients (EMPA-REG OUTCOME), yakabudiswa muNew England Journal of Medicine . Inenge imwecheteyo, mitsva yakazobudiswa paEuropean Association for the Study of Diabetes (EASD) 2015 musangano uye yakasangana nemitambo yakawanda yekutinhira kunobva kune vazhinji vepedocinologists varipo.
Kunyange zvazvo muedzo uyu wakangodzidza varwere vane chirwere cheshuga chechipiri, ndinofunga izvi zvinogona kuva mutambo wekushandura kwevatungamiri vehuga rega rega. Chidzidzo chacho hachina kungoratidza kuti mushonga, Empagliflozin, wakachengeteka asi wakaratidza zvakare kuti unokwanisa kugadzirisa matambudziko emwoyo nekukurumidza. Kukosha kweizvi hakugoni kuwedzererwa kubva kubva makumi mashanu kubva muzana yevakafa munyika yose kubva kune chirwere cheshuga chakakonzerwa nehutano hwehutano. Kusvikira ichi chidzidzo, kwete chirwere chimwe cheshuga cheshuga chakange chave chiratidzwa kuderedza dambudziko rehutano hwepfungwa nekufa kwevanhu vose. Pane kudaro, mishonga yakawanda yemishonga inoshandiswa kurapa chirwere cheshuga yakaratidzwa chete kuderedza zvinetso zve microvascular; izvo zvinowanzoitika kwenguva refu zvechirwere cheshuga chinosangana nemidziyo miduku yeropa. Izvi zvinyorwa zvinosanganisira retinopathy (kukuvara kwe retina), nephropathy (kukuvara kwetsvo), uye neuropathy (kukuvadza kumitsipa).
Empagliflozin is sodium- glucose co-transporter (SLGT-2) inhibitor. Mhando iyi yemishonga inoderedza huwandu hwemashuga eropa kuburikidza nekuvhara vatengesi, zvakakodzera zita raSGLT-2, izvo zvinotungamirira pakudzokorora glucose kubva kuitsvo muropa. Somugumisiro wekuvhara uku, shuga inogona kunge isina kukonzera kuverengera kwepamusoro yeglucose yeropa panzvimbo inowanikwa inoputira pasi chimbuzi.
Mukuwedzera kune kubatsirwa kwehuwandu hwemahemoglobin A1C , mishonga iyi inotungamirirawo kukurashika kwemahombekombe uye inoderera mukudzvinyirira kweropa.
SGLT-2 inhibitors vaiva FDA inogamuchirwa kuti iwane chirwere cheshuga chekutanga chekutanga muna 2013 uye inosanganisira mishonga yakadai seCanagliflozin (Invokana), Dapagliflozin (Farxiga), uye Empagliflozin (Jardiance).
Kunyange zvazvo mishonga iyi isati yabvumirwa kuti chirwere cheshuga chechirwere cheshuga, zvidzidzo zviduku zvakaratidza kuti SGLT-2 inhibitors inowedzera kugadzirisa zvirwere uye inokonzera kurasikirwa kwakakura kune varwere vane chirwere cheshuga cheshuga. Pasinei nekushayikwa kweDAA kuvhiringidzika kwechiratidzo ichi, vazhinji vepedocinologists vasati vashandisa SGLT-2 inhibitors kuti vabate varwere vavo vane chirwere cheshuga chechirwere cheshuga.
Mune EMPA-REG OUTCOME kudzidza, mhedzisiro yakaipa yemigumisiro yemwoyo yakaderedzwa ne14%. Nyaya yainyanya kufadza ndeyekuti kufa kwepfungwa, zvose-zvinokonzera rufu uye hospital hospitali yekukundikana kwemoyo zvose zvakaderedzwa neinopfuura 30%. Kukura kukuru kwechidzidzo ichi (vanopfuura 7000 varwere!) Kunoita kuti mukana usakanganise chikonzero chezviitiko zvinoshamisa.
Saizvozvowo kumanikidzira kwaiva kuwanikwa kuti kuderedzwa murufu uye hospitalist kwakatanga pakutanga mukudzidza. Izvi zvinoreva kuti kuderera kwemigumisiro hakukwanisi kuitika nekuda kwehuwandu hwehuga huri nani, kukanganiswa kweropa kuverengerwa kana kuora kwekureruka, sezvo migumisiro yekushanduka uku ingongotarisirwa kuratidza kwenguva refu.
Nokudaro, pane chimwe chinhu chisinganzwisisiki uye zvinogona kunge chichiita kuti zvive nyore kuchinja mupfungwa.
Mubvunzo wakanyatsojeka wakakonzerwa nechidzidzo ichi ndechokuti iyi ichinhu chinokanganisa chikamu kureva kuti vose SGLT-2 inhibitor vanobhadhara zvimwe zvakafanana nemagumisiro ekutsvaga dambudziko mumutambo kana kuti iyo inogumira kuEmpagliflozin here? Izvi zvinoramba zvichigadziriswa, asi ndinonzwa ndine chivimbo kuti zvidzidzo zvakafanana kushandisa Canagliflozin uye Dapagliflozin hazvigoni kuva kumashure. Ramba uchitarisa!